/
ANIX
$2.85+$0.06 (+2.15%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$94.9M
34M shares
52-week range
$2.32 – $5.46
17% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.75%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-1.00
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $250.0K | $0 | $512.0K | $0 | $210.0K | $0 | $0 |
| Cost of revenue | $1.1M | $166.3K | $90.2K | $385.0K | $0 | $161.0K | $0 | $36.0K |
| Gross profit | $18.8K | $83.8K | −$90.2K | $127.0K | $0 | $49.0K | $0 | −$36.0K |
| Gross margin | 1.7% | 33.5% | — | 24.8% | — | 23.3% | — | — |
| R&D | $6.8M | $5.5M | $4.4M | $6.2M | $6.7M | $4.8M | $6.4M | $5.1M |
| Operating income | −$13.7M | −$11.9M | −$10.0M | −$13.1M | −$13.9M | −$11.0M | −$13.8M | −$11.7M |
| EBITDA | −$13.9M | −$11.0M | −$10.0M | −$13.1M | −$13.7M | −$9.9M | −$12.7M | −$11.0M |
| Net income | −$14.0M | −$11.6M | −$10.1M | −$12.9M | −$13.6M | −$9.8M | −$12.6M | −$10.9M |
| Net margin | -1258.1% | -4658.8% | — | -2528.6% | — | -4671.9% | — | — |
| EPS (diluted) | -0.79 | -0.61 | -0.46 | -0.45 | -0.45 | -0.32 | -0.39 | -0.34 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-0.33 | $-0.33–$-0.33 | 1 |
| 2027 | $34M | $-0.34 | $-0.34–$-0.34 | 1 |
| 2028 | $0 | $-0.37 | $-0.40–$-0.34 | 2 |
| 2029 | $23M | $-0.43 | $-0.43–$-0.43 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.03
Price
$2.85
Implied downside
-99%
Peer comparison
Anixa Biosciences, Inc.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
www.anixa.com- Employees
- 4
- IPO / List date
- Oct 7, 1983
- HQ
- SAN JOSE, CA
Held by traders on TradeandTell
No one on the platform currently holds ANIX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 61,173 | $157.8K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ANIX yet.
